-
Novel Approaches Under Investigation
-
52 Week Efficacy and Safety of Etranacogene Dezaparvovec in Adults With Severe or Moderate-severe Hemophilia B: Data From the Phase 3 HOPE-B Gene Therapy Trial
-
9278 Shared Decistion Making IRL
-
A History of Hemophilia Treatment: Factor Replacement to Gene Therapy
-
A History of Hemophilia Treatment: Non-replacement Therapy to Gene Therapy
-
A New Tool to Assist in Treatment Selection–The World Federation of Hemophilia (WFH) Shared Decision-making (SDM) Tool
-
A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)
-
AAV Integration Summary and Implications
-
AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for Up to 5 Years
-
AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for Up to 5 Years
-
BeCoMe–9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
-
Bleeding Data Across Baseline FIX Expression Levels in People With Hemophilia B: An Analysis Using the ‘Factor Expression Study
-
Bleeding Outcomes in Participants With Factor VIII Activity
-
Clinical Outcomes in Adults With Hemophilia B With and Without Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data From the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial
-
Current Update of Clinical trials on Gene Therapy for Hemophilia
-
Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B
-
Dose Selection and Study Design for B-LIEVE, A Phase 1/2 Dose Confirmation Clinical Trial of FLT180A Gene Therapy for Patients with Hemophilia B
-
Durability of Gene Therapy
-
EAHAD Gene Therapy Working Group
-
Efficacy and Safety of Etranacogene Dezaparvovec in Adults With Severe or Moderate-severe Hemophilia B: First Data From the Phase 3 Hope-B Gene Therapy Trial